Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CureVac stock logo
CVAC
CureVac
$4.50
+1.2%
$3.49
$2.37
$5.28
$1.01B2.49726,521 shs300,653 shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$1.26
-0.4%
$1.01
$0.50
$1.55
$285.26M1.851.55 million shs512,297 shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$15.92
+2.6%
$14.43
$8.24
$18.38
$1.04B-0.3498,434 shs176,737 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$23.87
-0.4%
$20.69
$16.16
$26.55
$967.75M0.62202,638 shs100,865 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CureVac stock logo
CVAC
CureVac
-5.53%0.00%+27.95%+38.75%+9.90%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
+3.28%+8.62%+0.80%+3.28%+127.23%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-4.08%-2.02%-0.70%+47.25%+19.38%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
-1.44%-2.16%+22.73%+2.83%+39.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CureVac stock logo
CVAC
CureVac
4.1325 of 5 stars
3.52.00.04.83.20.01.3
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
4.0413 of 5 stars
3.52.00.04.73.61.70.0
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.6911 of 5 stars
3.51.00.00.02.75.00.0
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.7375 of 5 stars
0.83.02.51.13.63.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CureVac stock logo
CVAC
CureVac
3.00
Buy$11.00144.72% Upside
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.00
Buy$7.75517.53% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
3.00
Buy$38.00138.69% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$20.00-16.21% Downside

Current Analyst Ratings Breakdown

Latest GOSS, CVAC, MLYS, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
CureVac stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
5/8/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
4/30/2025
CureVac stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
4/17/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
4/15/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
4/2/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $42.00
3/18/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CureVac stock logo
CVAC
CureVac
$523.70M1.93N/AN/A$2.50 per share1.80
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$124.59M2.29N/AN/A$0.28 per share4.48
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.19B0.81$2.20 per share10.87$6.09 per share3.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CureVac stock logo
CVAC
CureVac
-$281.58M$0.928.18N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$179.82M-$0.23N/AN/AN/AN/A-127.28%-22.12%8/11/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.7849.7411.370.451.75%25.35%6.21%N/A

Latest GOSS, CVAC, MLYS, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
CureVac stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/15/2025Q1 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
5/7/2025Q3 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
4/10/2025Q4 2024
CureVac stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
3/18/2025Q4 2024
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.15-$0.15N/A-$0.15$7.02 million$9.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CureVac stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.482.01%N/A61.54%N/A

Latest GOSS, CVAC, MLYS, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CureVac stock logo
CVAC
CureVac
0.05
6.20
6.19
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.64
6.74
6.74
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
14.02
14.02
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37

Institutional Ownership

CompanyInstitutional Ownership
CureVac stock logo
CVAC
CureVac
17.26%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
CureVac stock logo
CVAC
CureVac
2.15%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
25.56%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
CureVac stock logo
CVAC
CureVac
880224.34 million219.07 millionOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.30 million215.27 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million33.27 millionOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.53 million20.22 millionOptionable

Recent News About These Companies

Best Growth Stocks to Buy for May 23rd
Best Value Stocks to Buy for May 23rd

New MarketBeat Followers Over Time

Media Sentiment Over Time

CureVac stock logo

CureVac NASDAQ:CVAC

$4.50 +0.06 (+1.24%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$1.25 -0.01 (-0.40%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$15.92 +0.40 (+2.58%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$23.87 -0.10 (-0.42%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.